{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:29:26Z","timestamp":1788553766773,"version":"build-2803163510"},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We prospectively evaluated the effect of anagrelide (ANA) on platelets, PF4, F1+2, PAP, PAI\u20101, and TFPI and erythromelalgia in patients with essential thrombocythemia (ET) receiving anti\u2010aggregants both pre\u2010 and post\u2010ANA. At first, we observed a successful reduction of platelets, which was associated with normalization of platelet coagulant and endothelial function and disappearance of erythromelalgia. Secondly, we found a correlation between PF4 and TFPI and between TFPI and thrombosis, suggesting that erythromelalgia may be caused by platelet\u2010mediated endothelial activation. These data may indicate that ANA may be efficacy in the treatment of symptomatic patients with ET. Am. J. Hematol. 80:81\u201383, 2005. \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.20399","type":"journal-article","created":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T20:19:26Z","timestamp":1125605966000},"page":"81-83","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide"],"prefix":"10.1002","volume":"80","author":[{"given":"Rossella R.","family":"Cacciola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cipolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Di Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Giustolisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V64.1.1.1"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01224.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1055\/s-0038-1649661","article-title":"Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI\u20101, t\u2010PA and vWF","volume":"70","author":"Bellucci S","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.200"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0037-1616518","article-title":"Structure and biology of tissue factor pathway inhibitor","volume":"86","author":"Bajai MS","year":"2001","journal-title":"Thromb Haemost"},{"issue":"2","key":"e_1_2_1_7_2","first-page":"9","article-title":"Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia","volume":"36","author":"Murphy S","year":"1999","journal-title":"Semin Hematol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602960000600307"},{"key":"e_1_2_1_9_2","first-page":"448","article-title":"Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide","volume":"60","author":"Laguna MS","year":"2000","journal-title":"Medicina (B Airs)"},{"issue":"3","key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1650579","article-title":"Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation","volume":"76","author":"van Genderen PJ","year":"1996","journal-title":"Thromb Haemost"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.20399","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.20399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T07:49:44Z","timestamp":1700207384000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.20399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1002\/ajh.20399"],"URL":"https:\/\/doi.org\/10.1002\/ajh.20399","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}